TG Therapeutics (TGTX) investor relations material

Executive summary

• Achieved strong Q2 2026 results with global revenue of $240.3 million and U.S. BRIUMVI net product revenue of $227.7 million, up 64% year-over-year, contributing to $445.3 million in revenue for the first half of 2026.

• Raised full-year 2026 global revenue guidance to $950 million and U.S. BRIUMVI net product revenue guidance to $890–905 million.

• Advanced pipeline with positive Phase 3 ENHANCE data for simplified IV dosing, progress on subcutaneous BRIUMVI, and expansion into new indications including myasthenia gravis and schizophrenia.

• Continued disciplined capital allocation, prioritizing investments in BRIUMVI, pipeline innovation, and selective share repurchases.

Financial highlights

• Q2 2026 net product revenue was $235.8 million (vs. $138.8 million Q2 2025); six months: $437.1 million (vs. $258.5 million 2025).

• Gross margin for U.S. business remained at 87%; total gross margin was 83%.

• Operating income for Q2 2026 was $21.7 million; six months: $56.5 million. Net income for Q2 2026: $7.8 million; six months: $27.6 million.

• Cash, cash equivalents, and investment securities totaled $612.3 million as of June 30, 2026.

Outlook and guidance

• Full-year 2026 global revenue target raised to $950 million; U.S. BRIUMVI net product revenue target raised to $890–905 million.

• Full-year operating expense guidance (R&D and SG&A) of $350–400 million, excluding non-cash compensation, plus $100 million for subcutaneous BRIUMVI manufacturing and start-up costs.

• Cash and projected revenues expected to fund operations for more than twelve months.